- Home
- IMMX vs RLYB Comparison
IMMX vs RLYB Comparison
Compare IMMX & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- RLYB
- Stock Information
- Founded
- IMMX 2014
- RLYB 2018
- Country
- IMMX United States
- RLYB United States
- Employees
- IMMX N/A
- RLYB N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- RLYB Health Care
- Exchange
- IMMX Nasdaq
- RLYB Nasdaq
- Market Cap
- IMMX 61.1M
- RLYB 14.4M
- IPO Year
- IMMX 2021
- RLYB 2021
- Fundamental
- Price
- IMMX $2.65
- RLYB $0.41
- Analyst Decision
- IMMX Strong Buy
- RLYB Hold
- Analyst Count
- IMMX 1
- RLYB 3
- Target Price
- IMMX $7.00
- RLYB $15.00
- AVG Volume (30 Days)
- IMMX 137.1K
- RLYB 8.1M
- Earning Date
- IMMX 08-11-2025
- RLYB 08-07-2025
- Dividend Yield
- IMMX N/A
- RLYB N/A
- EPS Growth
- IMMX N/A
- RLYB N/A
- EPS
- IMMX N/A
- RLYB N/A
- Revenue
- IMMX N/A
- RLYB $848,000.00
- Revenue This Year
- IMMX N/A
- RLYB N/A
- Revenue Next Year
- IMMX N/A
- RLYB N/A
- P/E Ratio
- IMMX N/A
- RLYB N/A
- Revenue Growth
- IMMX N/A
- RLYB N/A
- 52 Week Low
- IMMX $1.26
- RLYB $0.22
- 52 Week High
- IMMX $3.00
- RLYB $1.54
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- RLYB 55.26
- Support Level
- IMMX $2.16
- RLYB $0.32
- Resistance Level
- IMMX $2.80
- RLYB $0.61
- Average True Range (ATR)
- IMMX 0.17
- RLYB 0.05
- MACD
- IMMX 0.04
- RLYB 0.01
- Stochastic Oscillator
- IMMX 80.00
- RLYB 34.82
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.